摘要
Abstract
Objective:To investigate the efficacy of self-formulated Yiqi Jianpi decoction with modifications in treating intermediate to advanced stage non-small cell lung carcinoma(NSCLC)with lung and spleen Qi deficiency syndrome.Methods:A total of 80 intermediate to advanced stage NSCLC patients with lung and spleen Qi deficiency syndrome treated in a hospital from October 1,2022 to March 31,2024 were selected and assigned to the control group and observation group by random number table method,with 40 patients in each group.The control group was given GP scheme(gemcitabine hydrochloride for injection,cisplatin for injection),and the observation group was given self-formulated Yiqi Jianpi decoction with modifications in addition to the chemotherapy given in the control group.The immune function(CD3+,CD4+,CD8+,CD4+/CD8+),inflammatory factors[interleukin-2(IL-2),interleukin-12(IL-12),tumor necrosis factor-α(TNF-α)],tumor markers[glutathione S-transferase P1(GSTP1),carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)],Janus kinase 2(JAK2)/signal transducer and activator of transcription 3(STAT3)signaling pathway related indicators(JAK2 mRNA,STAT3 mRNA),traditional Chinese medicine(TCM)symptom score,clinical efficacy and adverse reactions were compared between the two groups.Results:After treatment,CD3+,CD4+and CD4+/CD8+in the observation group were higher than those in the control group(P<0.05),while CD8+in the observation group was lower than that in the control group(P<0.05).The levels of IL-2,IL-12,TNF-α,GSTP1,CA125,CEA,CYFRA21-1,JAK2 mRNA,STAT3 mRNA and TCM symptom scores were decreased in both groups(P<0.05),with the observation group showing lower levels than the control group(P<0.05).The objective remission rate in the observation group(62.50%)was higher than that in the control group(40.00%,P<0.05).No statistically significant difference was observed in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Self-formulated Yiqi Jianpi decoction with modifications can improve the clinical efficacy in intermediate to advanced stage NSCLC patients with lung and spleen Qi deficiency syndrome,inhibiting inflammatory factors,reducing the levels of tumor markers and alleviating immunosuppression.关键词
益气健脾汤/肺脾气虚型/非小细胞肺癌/炎症因子/肿瘤标志物/疗效Key words
Yiqi Jianpi decoction/lung and spleen Qi deficiency syndrome/non-small cell lung carcinoma/inflammatory factor/tumor marker/efficacy分类
医药卫生
